Developing therapies to improve quality of life in Alzheimer's disease
Established in 2016 in Heidelberg (Germany), EXCIVA is a privately held biotech company focused on developing clinical stage therapeutics for various indications in neuropsychiatry.
Our mission is to develop a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia read more
May 12, 2026
New Chairman
Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board.
April 28, 2026
First Patient
Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B
round.
January 20, 2026
Exciva raises €51 million
Exciva GmbH today announces the closing of a €51 million ($59m) Series B financing round.
Our vision
We aim to improve the quality of life and independence of patients, reduce distress for caregivers and support patients' families. Through cutting-edge research, rigorous clinical trials and collaboration with experts, we are dedicated to delivering the first-in-class and best-in-class treatments for neuropsychiatric symptoms of dementia.
Our ultimate vision is to restore dignity and quality of life of individuals affected by neuropsychiatric symptoms of dementia , provide comprehensive relief, and help transform the way dementia care is perceived and managed worldwide.